A Phase 1b Study of ACP-196 in Combination With Obinutuzumab for Patients With Relapsed / Refractory or Untreated CLL/SLL/PLL

Trial Profile

A Phase 1b Study of ACP-196 in Combination With Obinutuzumab for Patients With Relapsed / Refractory or Untreated CLL/SLL/PLL

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Acalabrutinib (Primary) ; Obinutuzumab; Rituximab; Venetoclax
  • Indications B cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Acerta Pharma
  • Most Recent Events

    • 12 Dec 2017 Results (Data cut off: 28 Apr, 2017) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 10 Dec 2017 Results published in an AstraZeneca Media Release
    • 10 Dec 2017 Results from this trial have been presented at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition, according to an AstraZeneca media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top